Clinical and Translational Imaging 投稿方向-刊鹿论文编译

Clinical and translational imaging keeps growing: thanks to its board members, authors and readership

Abstract:

Six years have gone by since the publication of the first issue of Clinical and Translational Imaging (CATI). At the beginning of its seventh year of life, CATI is progressively growing. The publication strategy is now very well defined, with full support of the Editorial Board and of the Publisher, as confirmed at our most recent editorial board meeting at EANM’18 in Düsseldorf where the attendees had a fruitful discussion. This Editorial is a brief report to the stakeholders on the status and outlook of the Journal. The goals that were set in the previous years have been achieved progressively, and the consideration in which our journal is held, by clinicians and scientists, is shown by the steeply increase of the number of downloads and citations. Undoubtedly, this result has been achieved thanks to the work of the entire Editorial Board. Thus, in this annual Editorial, I would like to express my appreciation to all those who, with a significant commitment, have contributed to the rise of the quality, performance, visibility and increase in citations and downloads of our Journal’s articles. I would like to ask at this time a consistency in support and submission of papers by the Editorial Board members. All of you, by active participation in meetings and personal relations with colleagues worldwide, can contribute to achieve a higher submission flow, guarantee high-quality papers and citations, as we are on the way of applying for the inclusion in the list of Journals with an official Impact Factor by Clarivate Analytics, the company that is now running the Web of Science database. Our content seems very interesting for our readership as it appears from the progression in ranking. The Journal has published since 2013 almost 300 timely updates on all scientific and clinical areas of molecular imaging, contributed by the authors worldwide; the content of each issue has become heterogeneous as we pursue the online publication, without delay, of submitted papers following the evaluation by at least two referees. We have a very fast revision and publication process, based on the very short time from submission to first decision (21 days in 2017) and from acceptance to online publication (14 days in 2017). A quick look at the Journal dashboard, that includes usage and impact data calculated from various databases, will tell you more about the Journal metrics. Over the last year we have expanded the editorial policy and review articles are classified according to four categories: meta-analyses, systematic reviews, expert reviews and mini-reviews. Furthermore, editorials, spotlight articles and pictorial essays enrich the Journal. As compared to previous years, we are receiving more spontaneous submissions and we also had an increase in the number of rejections. Papers are being submitted from all over the world with an increase from countries outside Europe and the USA. Papers related to the major areas of molecular imaging are collated and are easily retrievable under the heading “Article Collections” on the web page of the journal. The titles of the available article collections are displayed on SpringerLink to facilitate the search. CATI offers the option of Open Access publication, chosen by approximately 30% of the authors, which entails the immediate inclusion in PubMed. Furthermore, Springer allows authors to share their published article by means of the Springer Nature SharedIt link. To assist authors in disseminating their research to the broader community, Springer provides a free read-only version of the full-published article via a unique SharedIt link that can be generated by entering the DOI of the article. Moreover, by following our Facebook page, which has now more than 1000 followers, it is possible to obtain the sharable link for each paper as soon as it is published. News about the journal activity posted in various Facebook groups aimed at scientists and clinicians involved in nuclear medicine and molecular imaging reach regularly a targeted international readership. You are warmly invited to share with colleagues the Facebook posts. * G. Lucignani giovanni.lucignani@unimi.it

Author Listing： Giovanni Lucignani

Volume： 7

Pages： 1-2

DOI： 10.1007/s40336-019-00315-6

Language： English

Journal： Clinical and Translational Imaging

Clinical and Translational Imaging

CLIN TRANSL IMAGING

影响因子：1.6

是否综述期刊：否

是否OA：否

是否预警：不在预警名单内

发行时间：2013

ISSN：2281-5872

发刊频率：6 issues per year

收录数据库：SCIE/Scopus收录

出版国家/地区：ITALY

出版社：Springer International Publishing

期刊介绍

Clinical and Translational Imaging is an international journal that publishes timely, up-to-date summaries on clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes. Coverage includes such topics as advanced preclinical evidence in the fields of physics, dosimetry, radiation biology and radiopharmacy with relevance to applications in human subjects. The journal benefits a readership of nuclear medicine practitioners and allied professionals involved in molecular imaging and therapy.

临床和转化成像是一份国际期刊，及时发布临床实践和转化研究以及用于诊断和治疗目的的获批和实验性放射性药物的临床应用的最新摘要。覆盖范围包括物理学、剂量学、辐射生物学和放射性药物学领域中与人类受试者应用相关的先进临床前证据等主题。该杂志的读者群受益的核医学从业人员和相关专业人员参与分子成像和治疗。

年发文量	58
国人发稿量	8
国人发文占比	13.33%
自引率	8.7%
平均录取率	-
平均审稿周期	-
版面费	US$3860
偏重研究方向	Medicine-Radiology, Nuclear Medicine and Imaging
期刊官网	https://www.springer.com/40336/?utm_medium=display&utm_source=letpub&utm_content=text_link&utm_term=null&utm_campaign=MLSR_40336_AWA1_CN_CNPL_letpb_mp
投稿链接	https://www.editorialmanager.com/cati/

质量指标占比

研究类文章占比	OA被引用占比	撤稿占比	出版后修正文章占比
17.78%	25.00%	0.00%	2.56%

预警情况查看说明

时间	预警情况
2024年02月发布的2024版	不在预警名单中
2023年01月发布的2023版	不在预警名单中
2021年12月发布的2021版	不在预警名单中
2020年12月发布的2020版	不在预警名单中

JCR分区 WOS分区等级：Q3区

版本	按学科	分区
WOS期刊SCI分区 WOS期刊SCI分区是指SCI官方（Web of Science）为每个学科内的期刊按照IF数值排序，将期刊按照四等分的方法划分的Q1-Q4等级，Q1代表质量最高，即常说的1区期刊。（2021-2022年最新版）
	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING	Q3

关于2019年中科院分区升级版（试行）

分区表升级版（试行）旨在解决期刊学科体系划分与学科发展以及融合趋势的不相容问题。由于学科交叉在当代科研活动的趋势愈发显著，学科体系构建容易引发争议。为了打破学科体系给期刊评价带来的桎梏，“升级版方案”首先构建了论文层级的主题体系，然后分别计算每篇论文在所属主题的影响力，最后汇总各期刊每篇论文分值，得到“期刊超越指数”，作为分区依据。

分区表升级版（试行）的优势：一是论文层级的主题体系既能体现学科交叉特点，又可以精准揭示期刊载文的多学科性；二是采用“期刊超越指数”替代影响因子指标，解决了影响因子数学性质缺陷对评价结果的干扰。整体而言，分区表升级版（试行）突破了期刊评价中学科体系构建、评价指标选择等瓶颈问题，能够更为全面地揭示学术期刊的影响力，为科研评价“去四唯”提供解决思路。相关研究成果经过国际同行的认可，已经发表在科学计量学领域国际重要期刊。

《2019年中国科学院文献情报中心期刊分区表升级版（试行）》首次将社会科学引文数据库（SSCI）期刊纳入到分区评估中。升级版分区表（试行）设置了包括自然科学和社会科学在内的18个大类学科。基础版和升级版（试行）将过渡共存三年时间，推测在此期间各大高校和科研院所仍可能会以基础版为考核参考标准。提示：中科院分区官方微信公众号“fenqubiao”仅提供基础版数据查询，暂无升级版数据，请注意区分。

中科院分区查看说明

版本	大类学科	小类学科	Top期刊	综述期刊
	医学 4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学 4区	是	否
2021年12月基础版	医学 4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学 3区	是	否
2021年12月升级版	医学 4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学 4区	是	否
2020年12月旧的升级版	医学 4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学 4区	是	否
2022年12月最新升级版	医学 4区	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学 4区	是	否